

Understanding the Global Ankylosing Spondylitis Market: Trends, Treatment, and Projections to 2032

PORTLAND, OREGON, UNITED STATES, July 17, 2024 /EINPresswire.com/ --

https://www.alliedmarketresearch.com/purchase-enquiry/A10281

Market Overview

- Market Size and Growth: The global ankylosing spondylitis market was valued at \$5,140.94 million in 2020 and is expected to reach \$8,110.59 million by 2030, with a CAGR of 4.6% from 2021 to 2030.
- Disease Overview: Ankylosing spondylitis is an inflammatory disease causing spinal vertebrae fusion, leading

Global Ankylosing Spondylitis Market is projected to reach \$8,110.59 Million by 2030

Ankylosing Spondylitis Market: Trends, Treatment, and Projections

causing spinal vertebrae fusion, leading to reduced flexibility and potentially severe complications like breathing difficulties.

Symptoms and Diagnosis

- Early Signs: Includes morning stiffness, lower back and hip pain, neck pain, and fatigue.
- Diagnosis: Primarily through physical examination, supported by MRI and X-ray imaging.

Treatment and Management

- Current Approaches: Focus on symptom management as there is no known cure.
- Medications: NSAIDs, TNF inhibitors, corticosteroids, and DMARDs are commonly used.
- Emerging Therapies: Monoclonal antibodies like Taltz have shown efficacy in reducing inflammation and pain.

Market Drivers

- Prevalence: Increasing global prevalence, with significant screening results such as 7.3% positivity in Spain.
- Healthcare Infrastructure: Growth in orthopedic hospitals and diagnostic centers enhancing disease detection and treatment.

• Therapeutic Advancements: FDA approvals and advancements in therapy contribute to market expansion.

Market Segmentation

- By Drug Class: Dominated by NSAIDs; TNF inhibitors showing promising growth.
- By Distribution Channel: Major channels include hospital pharmacies, retail pharmacies, and online pharmacies.

Regional Insights

- North America: Largest market share due to high disease prevalence, robust healthcare infrastructure, and key player presence.
- Asia-Pacific: Expected highest growth rate (CAGR 6.1%) due to increasing healthcare facilities and population base.

Key Players

• Leading Companies: AbbVie, Amgen, Pfizer, Novartis, Lilly, among others, driving innovation and market growth.

Challenges

• Cost and Side Effects: High therapy costs and potential adverse drug effects pose challenges to market growth.

000000 000000 000000: https://www.alliedmarketresearch.com/purchase-enquiry/A10281

David Correa Allied Market Research

email us here

+1 800-792-5285

Visit us on social media:

Facebook

Χ

This press release can be viewed online at: https://www.einpresswire.com/article/728261800

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.